IDP-023

Indapta Therapeutics, INC. · Phase 1 active Small molecule

At a glance

Generic name	IDP-023
Sponsor	Indapta Therapeutics, INC.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers (PHASE1, PHASE2)
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IDP-023 CI brief — competitive landscape report
IDP-023 updates RSS · CI watch RSS
Indapta Therapeutics, INC. portfolio CI